Patents by Inventor Klaas Vandenbroucke
Klaas Vandenbroucke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230013523Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).Type: ApplicationFiled: June 6, 2022Publication date: January 19, 2023Applicant: INTREXON ACTOBIOTICS N.V.Inventors: Lothar STEIDLER, Klaas VANDENBROUCKE
-
Patent number: 11384123Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).Type: GrantFiled: September 21, 2020Date of Patent: July 12, 2022Assignee: INTREXON ACTOBIOTICS N.V.Inventors: Lothar Steidler, Klaas Vandenbroucke
-
Publication number: 20210163961Abstract: The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.Type: ApplicationFiled: December 4, 2020Publication date: June 3, 2021Applicant: INTREXON ACTOBIOTICS NVInventors: Klaas VANDENBROUCKE, Karolien VAN HUYNEGEM, Lothar STEIDLER
-
Patent number: 10988770Abstract: The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.Type: GrantFiled: February 15, 2018Date of Patent: April 27, 2021Assignee: INTREXON ACTOBIOTICS NVInventors: Klaas Vandenbroucke, Karolien Van Huynegem, Lothar Steidler
-
Publication number: 20210070815Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).Type: ApplicationFiled: September 21, 2020Publication date: March 11, 2021Applicant: INTREXON ACTOBIOTICS N.V.Inventors: Lothar STEIDLER, Klaas VANDENBROUCKE
-
Patent number: 10808014Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).Type: GrantFiled: September 11, 2017Date of Patent: October 20, 2020Assignee: INTREXON ACTOBIOTICS N.V.Inventors: Lothar Steidler, Klaas Vandenbroucke
-
Patent number: 10793825Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: December 13, 2019Date of Patent: October 6, 2020Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20200165564Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: December 13, 2019Publication date: May 28, 2020Applicant: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Patent number: 10519418Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC)activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP)activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: April 23, 2018Date of Patent: December 31, 2019Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20190194267Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).Type: ApplicationFiled: September 11, 2017Publication date: June 27, 2019Applicant: INTREXON ACTOBIOTICS N.V.Inventors: Lothar STEIDLER, Klaas VANDENBROUCKE
-
Publication number: 20180237739Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC)activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP)activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: April 23, 2018Publication date: August 23, 2018Applicant: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Patent number: 10030234Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: September 7, 2016Date of Patent: July 24, 2018Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20180187203Abstract: The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.Type: ApplicationFiled: February 15, 2018Publication date: July 5, 2018Applicant: INTREXON ACTOBIOTICS NVInventors: Klaas VANDENBROUCKE, Karolien VAN HUYNEGEM, Lothar STEIDLER
-
Patent number: 9982228Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: January 21, 2016Date of Patent: May 29, 2018Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20160376574Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: September 7, 2016Publication date: December 29, 2016Inventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Patent number: 9458467Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: September 21, 2012Date of Patent: October 4, 2016Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Patent number: 9347036Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: GrantFiled: September 21, 2012Date of Patent: May 24, 2016Assignee: INTREXON ACTOBIOTICS NVInventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20160137971Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Inventors: LOTHAR STEIDLER, KAROLIEN VAN HUYMEGEM, KLAAS VANDENBROUCKE
-
Patent number: 9017662Abstract: Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as Lactobacillus sp. and Saccharomyces sp., are disclosed for the treatment of chronic enterocolitis.Type: GrantFiled: August 30, 2006Date of Patent: April 28, 2015Assignee: Actogenix N.V.Inventors: Pieter Rottiers, Klaas Vandenbroucke
-
Publication number: 20140234371Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Inventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke